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brings another loss: the erosion of central
vision, making it impossible to drive or
read a book or see the contours of a loved
one’s face. No one knows what precipi-
tates age-related macular degeneration
(AMD), but it is the leading cause of vision
loss among the elderly in western coun-
tries. Aside from getting old, the major
risk factors for AMD include smoking
and having a genetic predisposition.
Approximately 15–20 million Americans
suffer from AMD, with about 200,000
new cases diagnosed each year and 3–4
million legally blind as a result. No cure
exists; current therapies can slow disease
progression in a limited number of cases,
but do not address the underlying cause.
The macula is a small patch in the mid-
dle of the retina that contains a high con-
centration of photoreceptor cells which
transmit visual signals to the brain and
governs central vision. Macular degener-
ation takes two forms: the early atrophic,
or ‘‘dry,’’ and the more advanced exuda-
tive, or ‘‘wet,’’ version. Most people de-
velop the early or intermediate dry form
of macular degeneration in which tiny de-
posits of protein and other cellular debris
called drusen accumulate on the macula.
Some patients with dry AMD are helped
by doses of vitamins and antioxidants.
The Age-Related Eye Disease Study
(AREDS) conducted by the National Eye
Institute (NEI) showed that antioxidant
supplements retarded progression of dry
AMD in about one-quarter of cases. NEI
is currently recruiting 4000 volunteers
for a new study to see the effect of anti-
oxidants (lutein and zeaxanthin) and/or
the long-chain omega-3 fatty acids DHA
and EPA.
In 10%–15% of patients, AMD abruptly
morphs into the more virulent wet type,
in which abnormal blood vessels grow
uncontrollably beneath the retina, dam-
age the macula, and leak blood and fluid.
This process, called choroidal neovascu-
larization (CNV), irreversibly damages the
photoreceptor cells.
The first FDA-approved treatment for
wet AMD was Visudyne (verteporfin) Pho-
todynamic Therapy (PDT) from QLT and
Novartis. Visudyne, a light-activated drug,
is injected intravenously to destroy tar-
geted blood vessels. Aside from surgery,
other approaches under development
include implants to deliver medication.
Sibling Rivalry
In the mid and late 1990s, it became in-
creasingly apparent that vascular endo-
thelial growth factor (VEGF) was a driver
for CNV. VEGF antagonists such as
Macugen (Pegaptanib), an injectable ribo-
nucleic aptamer, was developed by
Pfizer/Eyetech. Macugen was the first
VEGF antagonist to get approved, in
2004, but the current gold standard for
treating wet AMD is Genentech’s Lucentis
(ranibizumab), a humanized antibody
fragment that binds to different isoforms
of VEGF. Approved by the FDA in June
2006, Lucentis is administered by injec-
tion into the eye.
Lucentis is descended from the same
monoclonal antibody as Avastin (bevaci-
zumab), another Genentech anti-angio-
genic approved by the FDA in 2004 for
colorectal cancer. Meanwhile, waiting
for Lucentis approval, various groups
were experimenting with Avastin for wet
AMD. Dr. Philip Rosenfeld at the Bascom
Palmer Eye Institute reported the results
at the American Society of Retinal Spe-
cialists in 2005. Rosenfeld wrote in a later
paper ‘‘The option of using Avastin for
$17–$50 a dose is clearly more attractive
than PDT at $1500 a treatment or Lucentis
at $2000 a dose. Eventually, for us to
know which treatment is better, a head-
to-head clinical trial is necessary’’ (Rosen-
feld, 2006).
‘‘Six months later, hundreds of thou-
sands of eyes in the US used Avastin.’’ re-
called Dr. Daniel Martin, professor of
ophthalmology at Emory University Medi-
cal School and chair of the current NIH
phase III clinical trials comparing Lucentis
and Avastin. ‘‘It was remarkable, the clos-
est thing to penicillin we had ever seen.’’
Regeneron Hopes for a Bit
of Regeneration
A third player is now entering the Lucen-
tis/Avastin scrimmage. Tarrytown, NY,
based Regeneron (http://www.regn.com),
a public company, has a compound for
wet AMD, VEGF Trap-Eye, in phase III
clinical trials. Regeneron’s compound is
designed to bind VEGF and the related
Placental Growth Factor (PLGF). The
study is expected to enroll approximately
1,200 patients in North America and will
compare VEGF Trap-Eye to Lucentis. In
2006, Bayer Healthcare, LLC, struck a
collaboration for VEGF Trap-Eye of $75
million up front and $245 million in mile-
stone payments.
Regeneron’s VEGF Trap-Eye approach
involves attaching the binding portions of
two different receptors to the Fc fragment
of an antibody. This constructed molecule
blocks signaling proteins from binding
to receptors—impeding the formation
of leaky blood vessels. According to
Neil Stahl, Ph.D., senior vice president, re-
search and development sciences, the
VEGF Trap-Eye molecule is smaller than
Avastin by 50% but has 2000-fold
tighter binding than Avastin and 200 times
that of Lucentis, affinities arrived at in the
test tube but which need confirmation by
this clinical trial. ‘‘In the closed compart-
ment of the eye, you will get better block-
age at lower drug levels.’’ Stahl said. Re-
generon is maximizing the half-life of the
compound, an important consideration
for patients who have to endure injections
into their eyes. ‘‘A major goal of therapy is
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also looking at reversing the size of the
lesions.’’
Banking on Eyes
Gregory Hageman, professor of ophthal-
mology at the University of Iowa, became
interested in AMD in the late 1980s. ‘‘The
real issue is that there were no animal
models.’’ Hageman said. ‘‘We decided
to use human donor eyes to determine
what these drusen were comprised of.’’
Hageman accumulated 4000 pairs of
eyes, 1000 pairs from AMD patients. He
found the drusen contained proteins as-
sociated with the complement cascade,
a biochemical cascade which helps clear
pathogens from an organism, and hy-
pothesized that AMD was caused by in-
flammation. In 2005, Hageman and sev-
eral other groups found that AMD was
associated with variants of the comple-
ment factor B and complement factor H
genes. According to Hageman, these ge-
netic variants account for up to 3/4 of
cases of early AMD by producing defec-
tive proteins that cause immune system
malfunction.
Hageman is cofounder and chief
scientific officer of Optherion (http://
www.optherion.com), which focuses on
the earlier dry stage of AMD. Optherion
is located in New Haven, CT, and at the
University of Iowa. Instead of developing
a systemic inflammation inhibitor, Opthe-
rion’s approach will be to develop an aug-
mented protein protective against AMD.
Orchestrated by biotech investor David
Scheer, Optherion received $37 million in
financing last year from a consortium of
companies and venture capitalists. Op-
therion licensed its intellectual property
from the University of Iowa Research
Foundation, Yale, and the University of
Pittsburgh on chromosome 10.
No direct inflammatory trigger for AMD
has been found yet, although different
groups are proposing infections with
organisms like chlamydia. ‘‘The thing
about inflammation is that we don’t know304 Chemistry & Biology 15, April 2008 ª20whether it is the cause or the result of the
disease process.’’ says Margaret DeAnge-
lis, Ph.D., assistant professor of ophthal-
mology at Harvard Medical School and
Massachusetts Eye and Ear Infirmary.
Her group and others are studying the
entire complement pathway to identify its
precise role in AMD.
DeAngelis pointed out that while genes
like complement factor H have variants
associated with risk ‘‘.there are a lot of
people in the population walking around
with these variants that don’t have the dis-
ease.’’ And what causes dry AMD to turn
to wet AMD? ‘‘We’d love to know,’’ said
DeAngelis. Part of the problem, according
to DeAngelis, is lack of a good animal
model, as the mouse has a retina but not
a macula. ‘‘The identification of CFH was
a phenomenal stepping stone in begin-
ning to develop a molecular biochemical
profile for AMD risk’’ said DeAngelis.
‘‘From a chemical or biochemical stand-
point it will be important to correlate our
genetic findings at the protein level so
that appropriate agonists and antagonists
can be developed for treating this devas-
tating form of blindness.’’
Better Than a Poke in the Eye
If They Can Get It to Work
San Diego-based TargeGen (http://www.
targegen.com) hopes to dispense with
the eye injections entirely and administer
its wet macular degeneration, diabetic
macular edema, and diabetic retinopathy
treatment as eyedrops. The company’s
compound TG100801 is a benzotriazine
inhibitor that targets the VEGF pathway.
Specifically, their compound inhibits
VEGFFr2 and members of the SRC kinase
family. TargeGen has $36 million in
D-round financing.
TG100801 was developed as a prodrug,
an ester that is hydrolyzed by esterases to
have active effects in the back of the eye.
According to Richard Soll, Ph.D., vice
president of research and development
and chief scientific officer at TargeGen,
the challenge was designing a drug for08 Elsevier Ltd All rights reservedtwice daily dosing that could be rapidly
cleared from systemic circulation.
But TargeGen’s Phase II clinical trials to
look at the reduction of edema or leaks in
the eye were halted when brown-colored
microparticles of the compound ap-
peared just below the cornea. The com-
pany is weighing its options: either to con-
tinue testing it at a 303 lower dose in an
animal model, consider administering it
through a device, or switch to another
compound in the preclinical cupboard,
TG100948, from a different chemical fam-
ily. ‘‘We will make a decision that will
probably be made in context of a partner
to develop or not,’’ said Soll.
In another go-round, New Jersey-based
Ophthotech (http://www.ophthotech.
com) was inaugurated in 2007 with $36
million by former Eyetech execs to develop
therapies for both dry and wet AMD. The
company came with a dowry of three com-
pounds: the first, E10030, an anti-PDGF
aptamer, is entering a Phase I trial of up
to 36 patients. E10030 is being tested in
combination therapy with a VEGF-A inhib-
itor to see if it can roll back the angiogene-
sis of wet AMD. Additional compounds
include ARC1905, a complement (anti-
C5) inhibitor, and volociximab, an anti-an-
giogenesis monoclonal antibody-target-
ing a5b1 integrin. ARC1905 inhibits C5,
a trigger of inflammation, which is a part
of the complement cascade.
Companies like TargeGen, Optherion,
and Ophthotech are harbingers of new
strategies such as easier delivery and
combining drugs to knock off different
parts of the problem. However, ‘‘It is all
extremely early,’’ Martin said. ‘‘I think the
anti-VEGF therapies are likely to dominate
for a while.’’
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